English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The  RAD21  gene encodes a key component of the cohesin complex, which is essential for chromosome segregation, and together with BRCA1 and BRCA2, for high-fidelity DNA repair by homologous recombination. Although its expression correlates with early relapse and treatment resistance in sporadic breast cancers, it is unclear whether familial breast cancers behave in a similar manner.    Methods  We performed an immunohistochemical analysis of RAD21 expression in a cohort of 94 familial breast cancers (28 BRCA1, 27 BRCA2, and 39 BRCAX) and correlated these data with genotype and clinicopathologic parameters, including survival. In these cancers, we also correlated RAD21 expression with genomic expression profiling and gene copy-number changes and miRNAs predicted to target RAD21.    Results  No significant differences in nuclear RAD21 expression were observed between BRCA1 (12 (43%) of 28), BRCA2 (12 (44%) of 27), and BRCAX cancers (12 (33%) of 39 ( p  = 0.598). No correlation was found between RAD21 expression and grade, size, or lymph node, ER, or HER2 status (all  P  > 0.05). As for sporadic breast cancers, RAD21 expression correlated with shorter survival in grade 3 ( P  = 0.009) and but not in grade 1 ( P  = 0.065) or 2 cancers ( P  = 0.090). Expression of RAD21 correlated with poorer survival in patients treated with chemotherapy ( P  = 0.036) but not with hormonal therapy ( P  = 0.881). RAD21 expression correlated with shorter survival in BRCA2 ( P  = 0.006) and BRCAX ( P  = 0.008), but not BRCA1 cancers ( P  = 0.713). Changes in  RAD21  mRNA were reflected by genomic changes in DNA copy number ( P  < 0.001) and by RAD21 protein expression, as assessed with immunohistochemistry ( P  = 0.047). High  RAD21  expression was associated with genomic instability, as assessed by the total number of base pairs affected by genomic change ( P  = 0.048). Of 15 miRNAs predicted to target RAD21, mir-299-5p inversely correlated with RAD21 expression ( P  = 0.002).    Conclusions  Potential use of RAD21 as a predictive and prognostic marker in familial breast cancers is hence feasible and may therefore take into account the patient's BRCA1/2 mutation status.

Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers